Melanie Jean Coathup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Melanie Jean Coathup has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
Abinaya Sindu Pugazhendhi
12 shared publications- Sudipta Seal
Advanced Materials Processing and Analysis Center, Nanoscience Technology Center, University of Central Florida, Orlando, FL 32826, USA
12 shared publications Fei Wei
11 shared publicationsGordon W. Blunn
Institute of Orthopaedics and Musculoskeletal Science, Division of Surgery and Interventional Science, University College London, The Royal National Orthopaedic Hospital, Stanmore, Middlesex, HA7 4LP, UK
9 shared publications- Fei Wei
The Australia-China Centre for Tissue Engineering and Regenerative Medicine, Queensland University of Technology, Brisbane, QLD 4059, Australia
8 shared publications Mahmoud Omer
7 shared publications
Latest Publications
- 3 October 2026
- Published by Elsevier in Metabolism
- Vol. 185
P7C3: A novel multi-target therapeutic strategy to combat disuse-related bone loss in space and on earth
- 3 October 2026
- Published by Elsevier in Metabolism
- Vol. 185
P7C3: A novel multi-target therapeutic strategy to combat disuse-related bone loss in space and on earth
- 29 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (11) , e71975
Insights Into Dose‐Dependent Bone Toxicity Following Partial‐Body Exposure to Fractionated Ionizing Radiation In Vivo
Bone toxicity resulting from ionizing radiation (IR) is a major contributor to bone loss, fracture, pain, and morbidity. However, the precise mechanisms that drive its development remain largely unknown, and no effective medical countermeasure exists. Deciphering the molecular mechanism and mode of action as well as discerning molecular biomarker signatures that manifest proportionate to the dose and severity of injury is crucial in expediting the discovery and development of novel and effective diagnostic, prognostic, and treatment approaches. Herein, we investigate and compare the response to high dose IR during the transition of bone‐derived mesenchymal stem cells to osteoblasts and adipocytes, macrophages to osteoclasts, and late osteoblasts to mature osteocytes in vitro. Further, the counter response of bone to cumulative doses of 8, 16, and 24 Gy was assessed in vivo. Our findings indicate several novelties: cumulative radioresistance to DNA damage, apoptosis, reactive oxygen species formation, and dysfunctional mineral deposition was measured during osteoblast to osteocyte transition. Irradiation stimulated the formation of tunneling nanotube‐like structures, a novel type of intercellular communication machinery, in exposed macrophages. Bone fracture stress but not ultimate stress significantly decreased 48 h after a single 8 Gy exposure and prior to microarchitectural deterioration in vivo. Thus, early frailty‐inducing micromechanisms may originate within the organic/material component of bone independently of mechanical structure. Finally, data reveal dose‐ and severity‐related proteomic signatures of pathological toxicity. Engineered approaches that therapeutically target these fundamental cellular processes may offer a promising future strategy for the prevention and treatment of IR‐induced bone injury.
- 29 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (11) , e71975
Insights Into Dose‐Dependent Bone Toxicity Following Partial‐Body Exposure to Fractionated Ionizing Radiation In Vivo
Bone toxicity resulting from ionizing radiation (IR) is a major contributor to bone loss, fracture, pain, and morbidity. However, the precise mechanisms that drive its development remain largely unknown, and no effective medical countermeasure exists. Deciphering the molecular mechanism and mode of action as well as discerning molecular biomarker signatures that manifest proportionate to the dose and severity of injury is crucial in expediting the discovery and development of novel and effective diagnostic, prognostic, and treatment approaches. Herein, we investigate and compare the response to high dose IR during the transition of bone‐derived mesenchymal stem cells to osteoblasts and adipocytes, macrophages to osteoclasts, and late osteoblasts to mature osteocytes in vitro. Further, the counter response of bone to cumulative doses of 8, 16, and 24 Gy was assessed in vivo. Our findings indicate several novelties: cumulative radioresistance to DNA damage, apoptosis, reactive oxygen species formation, and dysfunctional mineral deposition was measured during osteoblast to osteocyte transition. Irradiation stimulated the formation of tunneling nanotube‐like structures, a novel type of intercellular communication machinery, in exposed macrophages. Bone fracture stress but not ultimate stress significantly decreased 48 h after a single 8 Gy exposure and prior to microarchitectural deterioration in vivo. Thus, early frailty‐inducing micromechanisms may originate within the organic/material component of bone independently of mechanical structure. Finally, data reveal dose‐ and severity‐related proteomic signatures of pathological toxicity. Engineered approaches that therapeutically target these fundamental cellular processes may offer a promising future strategy for the prevention and treatment of IR‐induced bone injury.
The Catalytic Activity and Micro‐Mechanisms of Reducible Metal Oxide Nanozymes in Relation to Their Antibacterial Efficacy
Precision‐driven nanomaterial approaches continue to show enormous promise and are forecast to transform contemporary medicine. The core strength lies in the ability to engineer materials at the nanoscale to achieve unique physicochemical properties. A theory that is paramount to its unlimited future promise is in creating “designer” or “intelligent” nanomaterials precisely crafted to enable specific biological interactions for applications in health, disease, and infection. Fuelled by their ease of synthesis, catalytic nature, complex surface character, and tunability, the development of next‐generation reducible metal oxide nanozymes (rNZs) that mimic the complex perceptive and adaptive capabilities of natural enzymes is a topic of remarkable curiosity. In pursuit of decoding rNZ catalytic mechanisms, this review spotlights the critical contribution of atomistic features. The promise of rNZs to circumvent the therapeutic insufficiencies surrounding bacterial antimicrobial resistance is confirmed to be a viable route forward, and the first evidence of the use of ionizing radiation to augment activity is presented as a novel antibacterial strategy. In some respects, the micromechanisms remain cryptic and elusive. The data reveal the critical contribution of crystal facets and oxygen vacancies within an orchestrated, heterogeneous, tunable, but strikingly complex system. Deciphering these sophisticated behaviors is arguably the next frontier in the field.
The Catalytic Activity and Micro‐Mechanisms of Reducible Metal Oxide Nanozymes in Relation to Their Antibacterial Efficacy
Precision‐driven nanomaterial approaches continue to show enormous promise and are forecast to transform contemporary medicine. The core strength lies in the ability to engineer materials at the nanoscale to achieve unique physicochemical properties. A theory that is paramount to its unlimited future promise is in creating “designer” or “intelligent” nanomaterials precisely crafted to enable specific biological interactions for applications in health, disease, and infection. Fuelled by their ease of synthesis, catalytic nature, complex surface character, and tunability, the development of next‐generation reducible metal oxide nanozymes (rNZs) that mimic the complex perceptive and adaptive capabilities of natural enzymes is a topic of remarkable curiosity. In pursuit of decoding rNZ catalytic mechanisms, this review spotlights the critical contribution of atomistic features. The promise of rNZs to circumvent the therapeutic insufficiencies surrounding bacterial antimicrobial resistance is confirmed to be a viable route forward, and the first evidence of the use of ionizing radiation to augment activity is presented as a novel antibacterial strategy. In some respects, the micromechanisms remain cryptic and elusive. The data reveal the critical contribution of crystal facets and oxygen vacancies within an orchestrated, heterogeneous, tunable, but strikingly complex system. Deciphering these sophisticated behaviors is arguably the next frontier in the field.
- 10 January 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (16) , e03961
A Novel Bone Shield to Improve Skeletal Health during Space Exploration and for Disuse Conditions on Earth
Bone loss due to disuse or mechanical unloading remains a significant space and Earth‐based medical challenge to resolve. The efficacy of cerium oxide nanoparticles (CeONPs) to mitigate weightlessness‐induced bone loss is unknown. Under gravity conditions in vitro, proteomic data reveal first evidence that during the early phase of osteogenesis, CeONPs augment osteoinduction, and osteoblast differentiation, survival, and proliferation via phosphoinositide 3‐kinase protein kinase B signaling. CeONPs suppress adipogenic differentiation by regulating cellular energy metabolism, inhibiting adipose accumulation, and by upregulating proteins capable of directing osteo‐adipogenic lineage fate toward osteogenesis over adipogenesis. Osteoclastogenesis is downregulated via c‐Jun‐N‐terminal kinase, nuclear factor kappa B, epidermal growth factor receptor, and extracellular signal regulated kinase 1/2 pathways, and by the CeONP‐mediated production of osteogenic factors within the osteoclast lineage cells. Following hind limb suspension (HLS), rapid, pathologic bone loss was measured in vivo. Notably, CeONP biodistribution reduced, potentially due to disadvantageous cephalad fluid shifts. Nevertheless, CeONP treatment buffers against oxidative stress, and significantly downregulates osteoclastic activation, bone resorption, bone marrow adiposity, and senescence, thereby maintaining a healthy bone structure despite HLS. These findings highlight CeONPs as a novel and promising therapeutic approach for addressing the skeletal challenges posed by microgravity and disuse conditions on Earth.
- 10 January 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (16) , e03961
A Novel Bone Shield to Improve Skeletal Health during Space Exploration and for Disuse Conditions on Earth
Bone loss due to disuse or mechanical unloading remains a significant space and Earth‐based medical challenge to resolve. The efficacy of cerium oxide nanoparticles (CeONPs) to mitigate weightlessness‐induced bone loss is unknown. Under gravity conditions in vitro, proteomic data reveal first evidence that during the early phase of osteogenesis, CeONPs augment osteoinduction, and osteoblast differentiation, survival, and proliferation via phosphoinositide 3‐kinase protein kinase B signaling. CeONPs suppress adipogenic differentiation by regulating cellular energy metabolism, inhibiting adipose accumulation, and by upregulating proteins capable of directing osteo‐adipogenic lineage fate toward osteogenesis over adipogenesis. Osteoclastogenesis is downregulated via c‐Jun‐N‐terminal kinase, nuclear factor kappa B, epidermal growth factor receptor, and extracellular signal regulated kinase 1/2 pathways, and by the CeONP‐mediated production of osteogenic factors within the osteoclast lineage cells. Following hind limb suspension (HLS), rapid, pathologic bone loss was measured in vivo. Notably, CeONP biodistribution reduced, potentially due to disadvantageous cephalad fluid shifts. Nevertheless, CeONP treatment buffers against oxidative stress, and significantly downregulates osteoclastic activation, bone resorption, bone marrow adiposity, and senescence, thereby maintaining a healthy bone structure despite HLS. These findings highlight CeONPs as a novel and promising therapeutic approach for addressing the skeletal challenges posed by microgravity and disuse conditions on Earth.
- Open Access
- 9 October 2024
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 166, 214063
The interaction of phosphate species with cerium oxide: The known, the ambiguous and the unexplained
- 9 October 2024
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 166, 214063
Open AccessThe interaction of phosphate species with cerium oxide: The known, the ambiguous and the unexplained
- Open Access
- 9 July 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (7) , 695
Emerging Medical Technologies and Their Use in Bionic Repair and Human Augmentation
As both the proportion of older people and the length of life increases globally, a rise in age-related degenerative diseases, disability, and prolonged dependency is projected. However, more sophisticated biomedical materials, as well as an improved understanding of human disease, is forecast to revolutionize the diagnosis and treatment of conditions ranging from osteoarthritis to Alzheimer’s disease as well as impact disease prevention. Another, albeit quieter, revolution is also taking place within society: human augmentation. In this context, humans seek to improve themselves, metamorphosing through self-discipline or more recently, through use of emerging medical technologies, with the goal of transcending aging and mortality. In this review, and in the pursuit of improved medical care following aging, disease, disability, or injury, we first highlight cutting-edge and emerging materials-based neuroprosthetic technologies designed to restore limb or organ function. We highlight the potential for these technologies to be utilized to augment human performance beyond the range of natural performance. We discuss and explore the growing social movement of human augmentation and the idea that it is possible and desirable to use emerging technologies to push the boundaries of what it means to be a healthy human into the realm of superhuman performance and intelligence. This potential future capability is contrasted with limitations in the right-to-repair legislation, which may create challenges for patients. Now is the time for continued discussion of the ethical strategies for research, implementation, and long-term device sustainability or repair.
- 9 July 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (7) , 695
Open AccessEmerging Medical Technologies and Their Use in Bionic Repair and Human Augmentation
As both the proportion of older people and the length of life increases globally, a rise in age-related degenerative diseases, disability, and prolonged dependency is projected. However, more sophisticated biomedical materials, as well as an improved understanding of human disease, is forecast to revolutionize the diagnosis and treatment of conditions ranging from osteoarthritis to Alzheimer’s disease as well as impact disease prevention. Another, albeit quieter, revolution is also taking place within society: human augmentation. In this context, humans seek to improve themselves, metamorphosing through self-discipline or more recently, through use of emerging medical technologies, with the goal of transcending aging and mortality. In this review, and in the pursuit of improved medical care following aging, disease, disability, or injury, we first highlight cutting-edge and emerging materials-based neuroprosthetic technologies designed to restore limb or organ function. We highlight the potential for these technologies to be utilized to augment human performance beyond the range of natural performance. We discuss and explore the growing social movement of human augmentation and the idea that it is possible and desirable to use emerging technologies to push the boundaries of what it means to be a healthy human into the realm of superhuman performance and intelligence. This potential future capability is contrasted with limitations in the right-to-repair legislation, which may create challenges for patients. Now is the time for continued discussion of the ethical strategies for research, implementation, and long-term device sustainability or repair.
- 28 June 2024
- Published by Elsevier in Biomaterials
- Vol. 311, 122683
Multifunctional scaffolds for bone repair following age-related biological decline: Promising prospects for smart biomaterial-driven technologies
- 28 June 2024
- Published by Elsevier in Biomaterials
- Vol. 311, 122683
Multifunctional scaffolds for bone repair following age-related biological decline: Promising prospects for smart biomaterial-driven technologies
- 18 March 2024
- Published by Elsevier in Biomaterials
- Vol. 307, 122527
A neoteric antibacterial ceria-silver nanozyme for abiotic surfaces
- 18 March 2024
- Published by Elsevier in Biomaterials
- Vol. 307, 122527
A neoteric antibacterial ceria-silver nanozyme for abiotic surfaces
- Open Access
- 13 March 2024
- Published by Wiley in Advanced Science
- Vol. 11 (21) , e2308698
A Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis
By 2060, an estimated one in four Americans will be elderly. Consequently, the prevalence of osteoporosis and fragility fractures will also increase. Presently, no available intervention definitively prevents or manages osteoporosis. This study explores whether Pool 7 Compound 3 (P7C3) reduces progressive bone loss and fragility following the onset of ovariectomy (OVX)‐induced osteoporosis. Results confirm OVX‐induced weakened, osteoporotic bone together with a significant gain in adipogenic body weight. Treatment with P7C3 significantly reduced osteoclastic activity, bone marrow adiposity, whole‐body weight gain, and preserved bone area, architecture, and mechanical strength. Analyses reveal significantly upregulated platelet derived growth factor‐BB and leukemia inhibitory factor, with downregulation of interleukin‐1 R6, and receptor activator of nuclear factor kappa‐B (RANK). Together, proteomic data suggest the targeting of several key regulators of inflammation, bone, and adipose turnover, via transforming growth factor‐beta/SMAD, and Wingless‐related integration site/be‐catenin signaling pathways. To the best of the knowledge, this is first evidence of an intervention that drives against bone loss via RANK. Metatranscriptomic analyses of the gut microbiota show P7C3 increased Porphyromonadaceae bacterium, Candidatus Melainabacteria, and Ruminococcaceae bacterium abundance, potentially contributing to the favorable inflammatory, and adipo‐osteogenic metabolic regulation observed. The results reveal an undiscovered, and multifunctional therapeutic strategy to prevent the pathological progression of OVX‐induced bone loss.
- 13 March 2024
- Published by Wiley in Advanced Science
- Vol. 11 (21) , e2308698
Open AccessA Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis
By 2060, an estimated one in four Americans will be elderly. Consequently, the prevalence of osteoporosis and fragility fractures will also increase. Presently, no available intervention definitively prevents or manages osteoporosis. This study explores whether Pool 7 Compound 3 (P7C3) reduces progressive bone loss and fragility following the onset of ovariectomy (OVX)‐induced osteoporosis. Results confirm OVX‐induced weakened, osteoporotic bone together with a significant gain in adipogenic body weight. Treatment with P7C3 significantly reduced osteoclastic activity, bone marrow adiposity, whole‐body weight gain, and preserved bone area, architecture, and mechanical strength. Analyses reveal significantly upregulated platelet derived growth factor‐BB and leukemia inhibitory factor, with downregulation of interleukin‐1 R6, and receptor activator of nuclear factor kappa‐B (RANK). Together, proteomic data suggest the targeting of several key regulators of inflammation, bone, and adipose turnover, via transforming growth factor‐beta/SMAD, and Wingless‐related integration site/be‐catenin signaling pathways. To the best of the knowledge, this is first evidence of an intervention that drives against bone loss via RANK. Metatranscriptomic analyses of the gut microbiota show P7C3 increased Porphyromonadaceae bacterium, Candidatus Melainabacteria, and Ruminococcaceae bacterium abundance, potentially contributing to the favorable inflammatory, and adipo‐osteogenic metabolic regulation observed. The results reveal an undiscovered, and multifunctional therapeutic strategy to prevent the pathological progression of OVX‐induced bone loss.
- Open Access
- 5 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 3024
Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection
The human skeleton is a metabolically active system that is constantly regenerating via the tightly regulated and highly coordinated processes of bone resorption and formation. Emerging evidence reveals fascinating new insights into the role of sphingolipids, including sphingomyelin, sphingosine, ceramide, and sphingosine-1-phosphate, in bone homeostasis. Sphingolipids are a major class of highly bioactive lipids able to activate distinct protein targets including, lipases, phosphatases, and kinases, thereby conferring distinct cellular functions beyond energy metabolism. Lipids are known to contribute to the progression of chronic inflammation, and notably, an increase in bone marrow adiposity parallel to elevated bone loss is observed in most pathological bone conditions, including aging, rheumatoid arthritis, osteoarthritis, and osteomyelitis. Of the numerous classes of lipids that form, sphingolipids are considered among the most deleterious. This review highlights the important primary role of sphingolipids in bone homeostasis and how dysregulation of these bioactive metabolites appears central to many chronic bone-related diseases. Further, their contribution to the invasion, virulence, and colonization of both viral and bacterial host cell infections is also discussed. Many unmet clinical needs remain, and data to date suggest the future use of sphingolipid-targeted therapy to regulate bone dysfunction due to a variety of diseases or infection are highly promising. However, deciphering the biochemical and molecular mechanisms of this diverse and extremely complex sphingolipidome, both in terms of bone health and disease, is considered the next frontier in the field.
- 5 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 3024
Open AccessSphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection
The human skeleton is a metabolically active system that is constantly regenerating via the tightly regulated and highly coordinated processes of bone resorption and formation. Emerging evidence reveals fascinating new insights into the role of sphingolipids, including sphingomyelin, sphingosine, ceramide, and sphingosine-1-phosphate, in bone homeostasis. Sphingolipids are a major class of highly bioactive lipids able to activate distinct protein targets including, lipases, phosphatases, and kinases, thereby conferring distinct cellular functions beyond energy metabolism. Lipids are known to contribute to the progression of chronic inflammation, and notably, an increase in bone marrow adiposity parallel to elevated bone loss is observed in most pathological bone conditions, including aging, rheumatoid arthritis, osteoarthritis, and osteomyelitis. Of the numerous classes of lipids that form, sphingolipids are considered among the most deleterious. This review highlights the important primary role of sphingolipids in bone homeostasis and how dysregulation of these bioactive metabolites appears central to many chronic bone-related diseases. Further, their contribution to the invasion, virulence, and colonization of both viral and bacterial host cell infections is also discussed. Many unmet clinical needs remain, and data to date suggest the future use of sphingolipid-targeted therapy to regulate bone dysfunction due to a variety of diseases or infection are highly promising. However, deciphering the biochemical and molecular mechanisms of this diverse and extremely complex sphingolipidome, both in terms of bone health and disease, is considered the next frontier in the field.